

CITATION REPORT

List of articles citing

Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders

DOI: 10.1016/s0006-3223(01)01206-9
Biological Psychiatry, 2002, 51, 253-60.

Source: <https://exaly.com/paper-pdf/34081956/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
92	Management commentary. 252-258		
91	Newer anticonvulsant drugs in neuropathic pain and bipolar disorder. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2002 , 16, 19-37	0.8	10
90	Antikonvulsiva. <i>Krankenhauspsychiatrie</i> , 2002 , 13, 44-48		0
89	Presentations of depression in bipolar illness. <i>Clinical Neuroscience Research</i> , 2002 , 2, 142-157		9
88	Early psychosocial stressors: relationship to suicidality and course of bipolar illness. <i>Clinical Neuroscience Research</i> , 2002 , 2, 161-170		15
87	Acute and prophylactic effects of anticonvulsants in bipolar depression. <i>Clinical Neuroscience Research</i> , 2002 , 2, 228-251		14
86	Current Awareness. <i>Human Psychopharmacology</i> , 2002 , 17, 201-212	2.3	
85	Do the epilepsies, pain syndromes, and affective disorders share common kindling-like mechanisms?. <i>Epilepsy Research</i> , 2002 , 50, 203-19	3	48
84	Clinical studies implementing glutamate neurotransmission in mood disorders. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1003, 292-308	6.5	131
83	Unique design issues in clinical trials of patients with bipolar affective disorder. <i>Journal of Psychiatric Research</i> , 2003 , 37, 61-73	5.2	33
82	Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. <i>Bipolar Disorders</i> , 2003 , 5, 110-4	3.8	72
81	An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). <i>Bipolar Disorders</i> , 2003 , 5, 310-9	3.8	106
80	Lamotrigine: a review of its use in bipolar disorder. <i>Drugs</i> , 2003 , 63, 2029-50	12.1	120
79	Lamotrigine in mood disorders. <i>Current Medical Research and Opinion</i> , 2003 , 19, 272-7	2.5	89
78	Recent developments in the treatment of bipolar disorders. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 1621-32	5.9	6
77	The evolution of antiepileptic drugs for mood stabilization and their main mechanisms of action. <i>Expert Review of Neurotherapeutics</i> , 2003 , 3, 107-18	4.3	3
76	Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 484-95	1.7	95

75	Hypothermia in a hemodialysis patient treated with olanzapine monotherapy. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 314	1.7	13
74	Assessment of QTc prolongation following thioridazine withdrawal in a developmentally disabled population. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 314-5	1.7	1
73	Effects of selective serotonin reuptake inhibitors on cholesterol levels in patients with panic disorder. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 317-9	1.7	14
72	Lamotrigine augmentation in unipolar depression. <i>International Clinical Psychopharmacology</i> , 2003 , 18, 97-9	2.2	38
71	Neuroleptic malignant syndrome following administration of risperidone and lithium. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 315-7	1.7	17
70	Bipolar Disorder and Crossover Design. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 320	1.7	
69	Antidepressant properties of anticonvulsant drugs for bipolar disorder. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 182-92	1.7	32
68	Bipolar disorder and crossover design. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 319-20; author reply 320	1.7	
67	New Uses for Lithium and Anticonvulsants. <i>Harvard Review of Psychiatry</i> , 2003 , 11, 230-244	4.1	5
66	What is a "mood stabilizer"? An evidence-based response. <i>American Journal of Psychiatry</i> , 2004 , 161, 3-18	1.9	313
65	Neurobiology of seizures and behavioral abnormalities. <i>Epilepsia</i> , 2004 , 45 Suppl 2, 5-14	6.4	71
64	Differing psychotropic profiles of the anticonvulsants in bipolar and other psychiatric disorders. <i>Clinical Neuroscience Research</i> , 2004 , 4, 9-30		14
63	Convergences in course of illness and treatments of the epilepsies and recurrent affective disorders. <i>Clinical EEG and Neuroscience</i> , 2004 , 35, 14-24	2.3	23
62	Behavioural effects of the newer antiepileptic drugs: an update. <i>Expert Opinion on Drug Safety</i> , 2004 , 3, 1-8	4.1	67
61	Beyond monoamines: glutamatergic function in mood disorders. <i>CNS Spectrums</i> , 2005 , 10, 808-19	1.8	215
60	A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005 , 44, 539-47	7.2	118
59	GABA and glutamate systems as therapeutic targets in depression and mood disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2005 , 9, 153-68	6.4	112
58	Complex Combination Therapy: The Evolution Toward Rational Polypharmacy in Lithium-Resistant Bipolar Illness. 2006 , 135-167		1

57	The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. <i>CNS Spectrums</i> , 2006 , 11, 788-99	1.8	25
56	Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. <i>Neuropsychopharmacology</i> , 2007 , 32, 2490-9	8.7	183
55	Combined biological tests for suicide prediction. <i>Psychiatry Research</i> , 2007 , 150, 187-91	9.9	62
54	Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. <i>CNS Drugs</i> , 2007 , 21, 47-71	6.7	44
53	Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. <i>Biological Psychiatry</i> , 2007 , 61, 162-6	7.9	117
52	Role of GABA in anxiety and depression. <i>Depression and Anxiety</i> , 2007 , 24, 495-517	8.4	335
51	Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. <i>Bipolar Disorders</i> , 2007 , 9, 551-60	3.8	90
50	Gabapentin in the treatment of mental illness: the echo chamber of the case series. <i>Journal of Psychiatric Practice</i> , 2008 , 14 Suppl 1, 15-27	1.3	8
49	Anticonvulsants in the treatment of major depressive disorder: an overview. <i>Harvard Review of Psychiatry</i> , 2009 , 17, 231-41	4.1	49
48	How reviews covered the unfolding scientific story of gabapentin for bipolar disorder. <i>General Hospital Psychiatry</i> , 2009 , 31, 279-87	5.6	7
47	Geschlechtsunterschiede in der Psychopharmakologie [Gendermedizin in der Psychiatrie. <i>Psychiatrie Und Psychotherapie</i> , 2009 , 5, 64-69		2
46	Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. <i>PLoS ONE</i> , 2010 , 5, e11895	3.7	16
45	Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. <i>Human Genomics and Proteomics</i> , 2010 , 2010, 159761		17
44	Differential modulation of intracellular Ca ²⁺ responses in B lymphoblasts by mood stabilizers. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 693-702	5.8	15
43	A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. <i>CNS Neuroscience and Therapeutics</i> , 2010 , 16, 91-102	6.8	48
42	Premenstrual dysphoric disorder in women with epilepsy: relationships to potential epileptic, antiepileptic drug, and reproductive endocrine factors. <i>Epilepsy and Behavior</i> , 2011 , 21, 391-6	3.2	2
41	How can we classify "mood stabilizers" with different properties?. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2011 , 2, 12-23	0.2	2
40	Duration of illness and duration of untreated illness in relation to drug response in psychiatric disorders. <i>Neuropsychiatry</i> , 2011 , 1, 81-90	1.8	25

39	Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. <i>Psychiatric Quarterly</i> , 2012 , 83, 371-83	4.1	21
38	Management commentary. 247-253		
37	Neurobiological correlates of illness progression in the recurrent affective disorders. <i>Journal of Psychiatric Research</i> , 2012 , 46, 561-73	5.2	112
36	A factor analytic study in bipolar depression, and response to lamotrigine. <i>CNS Spectrums</i> , 2013 , 18, 214-28	2.8	14
35	Understanding the pharmacokinetics of anxiolytic drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 423-40	5.5	56
34	Novel glutamatergic drugs for the treatment of mood disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 1101-12	3.1	68
33	A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 101-11	3.1	10
32	Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. <i>CNS Spectrums</i> , 2014 , 19, 121-33	1.8	101
31	Bipolar (Manic Depressive) Disorders. 2015 , 857-901		1
30	The Disconnect between initial judgments of lamotrigine vs. its real-world effectiveness in managing bipolar disorder. A tale with wider ramifications. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 132, 345-54	6.5	10
29	Is duration of illness really influencing outcome in major psychoses?. <i>Nordic Journal of Psychiatry</i> , 2015 , 69, 403-17	2.3	30
28	Relinquishment of Inappropriate Off-Label Uses: The Effect of the False Claims Act. <i>SSRN Electronic Journal</i> , 2016 ,	1	
27	Areas of controversy in neuroprogression in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2016 , 134, 91-103	6.5	145
26	A critical overview of the clinical evidence supporting the concept of neuroprogression in bipolar disorder. <i>Psychiatry Research</i> , 2016 , 235, 1-6	9.9	20
25	Treatment of Bipolar Depression: Evolving Recommendations. <i>Psychiatric Clinics of North America</i> , 2016 , 39, 11-33	3.1	22
24	Role of calcium, glutamate and NMDA in major depression and therapeutic application. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 64, 325-33	5.5	78
23	Should bipolar disorder treatment be modified depending on staging?. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 93-95	4.3	8
22	Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017 , 7, e013433	3	27

21	The Link between Refractoriness and Neuroprogression in Treatment-Resistant Bipolar Disorder. <i>Modern Problems of Pharmacopsychiatry</i> , 2017 , 31, 10-26		18
20	Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. <i>Journal of Affective Disorders</i> , 2017 , 208, 560-566	6.6	32
19	Neuroprogression and illness trajectories in bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 277-285	4.3	70
18	Utilization of gabapentin by people in treatment for substance use disorders in Belgium (2011-2014): a cross-sectional study. <i>Archives of Public Health</i> , 2018 , 76, 17	2.6	3
17	Irritability in a mixed sample of patients with unipolar and bipolar II depression predicts responsiveness to lamotrigine. <i>Personalized Medicine in Psychiatry</i> , 2018 , 7-8, 27-30	1.1	3
16	Management Commentary. 2019 , 255-262		1
15	Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2019 , 10, 228	5	31
14	Personalized treatment in bipolar disorder. 2020 , 423-436		1
13	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 230-256	5.8	11
12	Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets. <i>Expert Opinion on Therapeutic Targets</i> , 2020 , 24, 1187-1209	6.4	8
11	A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
10	Psychotropic Mechanisms of Action of Antiepileptic Drugs in Mood Disorder. <i>Medical Psychiatry</i> , 2008 , 379-400		3
9	Clinical predictors of ketamine response in treatment-resistant major depression. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, e417-23	4.6	100
8	Gabapentin Therapy in Psychiatric Disorders: A Systematic Review. <i>primary care companion for CNS disorders, The</i> , 2015 , 17,	1.2	25
7	Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020 , 18, 599-606	3.4	7
6	Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2021 , 11, 20451253211045870	4.9	3
5	Treatment of Bipolar Depression. 2004 , 165-197		
4	The Kindling/Sensitization Model: Implications for the Pathophysiology of Bipolar Disorder. <i>Medical Psychiatry</i> , 2007 , 297-323		

3 Treatment of Bipolar Depression. **2011**, 197-237

2 Bipolar Illness. **2016**, 53-78

1 The role of lamotrigine in the management of bipolar disorder. *Neuropsychiatric Disease and Treatment*, **2007**, 3, 463-74

3.1 20